Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relative Bioavailability and Food Effect of HRS-8080 in Healthy Subjects
NCT06619873Phase 1Completed
- Sponsor
- Shandong Suncadia Medicine Co., Ltd.
- Start
- Oct 2024
- Primary completion
- Nov 2024
- Modality
- Molecular Glues
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of HRS-8080 in breast cancer (4 arms), sponsored by Shandong Suncadia Medicine Co., Ltd. Primary endpoints: Maximum Observed Plasma Concentration, Area Under the Plasma Concentration-Time Curve From Time Zero to the Last Quantifiable Concentration and 1 more. Started Oct 2024; status: completed.
02
Drugs
HRS-8080
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06619873.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06619873.